Table 2 Subgroup analysis by defining HER2 status by Hoffman validation criteria

Sex

18

1.34(1.15, 1.56)

<0.001

0.0

0.716

15

1.63(1.41, 1.89)

<0.001

42.4

0.042

Age

13

1.01(0.72, 1.41)

0.976

72.0

0.000

14

0.78(0.62, 0.99)

0.038

45.6

0.032

Tumor size

7

0.94(0.70, 1.26)

0.692

0.0

0.486

4

0.55(0.32, 0.96)

0.070

12.6

0.330

Tumor site

10

1.06(0.83, 1.37)

0.632

25.3

0.211

14

1.40(1.14, 1.71)

0.001

25.2

0.182

Lauren’s classification

17

3.67(2.47, 5.47)

<0.001

76.2

<0.001

13

3.03(1.95,4.70)

<0.001

73.4

<0.001

Differentiation grade

16

1.24(0.76, 2.05)

0.390

74.8

<0.001

12

2.71(1.66, 4.44)

<0.001

76.8

<0.001

TNM stage (III+IV vs I+II)

14

1.53(1.05,2.23)

0.026

77.4

<0.001

10

1.23(1.04,1.46)

0.014

0.0

0.939

Lymph node metastasis

13

1.15(1.00, 1.33)

0.057

0.0

0.500

14

1.40(1.19, 1.64)

<0.001

0.0

0.847

Distant metastasis

5

2.58(1.00, 6.67)

0.050

64.8

0.023

4

1.52(1.18, 1.95)

0.001

0.0

0.617

Lymphovascular invasion

6

1.18(0.75, 1.85)

0.468

74.1

0.002

4

2.16(0.87, 5.35)

0.096

0.0

0.421

Overall survival

4

1.95(1.38, 2.51)

<0.001

0.0

0.583

6

1.11(0.68, 1.53)

<0.001

70.8

0.004